An iPSC line derived from a human acute myeloid leukemia cell line (HL-60-iPSC) retains leukemic abnormalities and displays myeloid differentiation defects
Summary
Cancer-derived iPSCs have provided valuable insight into oncogenesis, but human cancer cells can often be difficult to reprogram, especially in cases of complex genetic abnormalities. Here we report, to our knowledge, the first successful generation of an iPSC line from a human immortalized acute myeloid leukemia (AML) cell line, the cell line HL-60. This iPSC line retains a majority of the leukemic genotype and displays defects in myeloid differentiation, thus providing a tool for modeling and studying AML. Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
| Authors | Yamasaki AE, Warshaw JN, Kyalwazi BL, Matsui H, Jepsen K, Panopoulos AD |
|---|---|
| Journal | Stem cell research |
| Publication Date | 2020 Dec;49:102096 |
| PubMed | 33370871 |
| PubMed Central | PMC8031422 |
| DOI | 10.1016/j.scr.2020.102096 |